UNSPSC 51151642: Flavoxate

This classification denotes an antimuscarinic agent with the molecular formula C24H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E74Y80MEY, chemically known as 4h-1-benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-piperidinoethyl ester, hydrochloride but generally known as flavoxate, which bears US NIH Compound Identifier 3354. European Medicines Agency schedules Flavoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07635MIG.

UNSPSC 51151642 Flavoxate is a Commodity code that covers pharmaceutical products, but the recent state and local opportunities posted under it do not reflect flavoxate procurement — instead, they capture naloxone and direct-to-manufacturer prescription program sourcing. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county's community health building and a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to gather vendor capabilities around a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, exploring how to establish relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code's nominal scope and these recent opportunities suggests limited current state and local procurement activity specifically for flavoxate products.

Geographic activity centers on Florida and Texas in the recent opportunities block. Seminole County's naloxone procurement is the only concrete solicitation with a firm response deadline (July 26, 2023, per the source data) and specific unit quantities and delivery location. The Texas HHS RFI represents exploratory market intelligence gathering with no budget commitment, award value, or formal evaluation criteria at the information stage. Both issuing bodies are county-level and state health authorities, signaling that pharmaceutical procurement under this code originates from public health and human services departments rather than school districts or transit authorities. Set-asides and disadvantaged-enterprise preferences are not mentioned in either opportunity.